Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$2.50
-$0.05(-4.10%)
At close: 4:00 PM EDT
$2.50
-$0.05(-4.10%)
Day’s Range― - ―
52-Week Range$1.13 - $2.89
Previous CloseN/A
Volume238.62K
Average Volume (3M)271.84K
Market Cap
$75.16M
Enterprise Value$55.32M
Total Cash (Recent Filing)$55.84M
Total Debt (Recent Filing)$56.21M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Oct 27, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding42,948,270
10 Day Avg. Volume302,304
30 Day Avg. Volume271,844
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit0.82
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$3.50Price Target Upside40.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$90.54M
Bulls Say, Bears Say
Bulls Say
Gross Margin And Cost DisciplineHigher gross margin and lower operating expenses indicate improving operating leverage in Pulmonx’s procedure-driven model. If these gains persist, they can reduce the revenue needed to approach break-even, preserve cash longer, and strengthen the economics of future center expansion.
Improving Liquidity FlexibilityReduced expected cash burn, substantial cash on hand, and a longer debt maturity give Pulmonx more time to execute its commercial strategy without immediate refinancing pressure. The additional funding runway can support treating-center growth while management works toward sustained sales growth.
Commercial And Regulatory ExpansionAdding treating centers expands the infrastructure through which Zephyr procedures can be delivered, while renewed Chinese registration restores a path to future shipments. Growth outside China also demonstrates that the business has multiple geographic avenues for longer-term adoption.
Bears Say
Persistent Unprofitability And Cash BurnPulmonx remains materially dependent on external funding or existing liquidity because operating losses are translating into substantial cash consumption. Continued losses reduce financial flexibility and make execution on center expansion more sensitive to revenue timing and demand volatility.
Revenue Contraction And China DisruptionRecent revenue contraction shows that the commercial platform has not yet converted operational improvements into durable top-line growth. The delayed China recovery leaves a meaningful geographic headwind, increasing reliance on U.S. and other international markets to carry near-term expansion.
Rising Leverage And Shrinking EquityHigher leverage alongside declining equity reduces the balance-sheet cushion available to absorb continued losses. If profitability takes longer to arrive, Pulmonx may face greater financing constraints and less flexibility to fund commercial investment or withstand revenue setbacks.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.13 and its highest was $2.89 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $75.16M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Oct 27, 2026 which is in 6 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Jul 29, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.04.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.26.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,948,270 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 28.8%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (40.00% Upside)
$3.50 (40.00% Upside)
Blogger Sentiment
Bearish
LUNG Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 112.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $167.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.98%
12-Months-Change
Fundamentals
Return on Equity
-96.66%
Trailing 12-Months
Asset Growth
-22.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pulmonx
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic picture: multiple operational and financial improvements (notably a nearly 40% reduction in adjusted EBITDA loss, 16% YoY reduction in operating expenses, gross margin expansion, China registration renewal, filled U.S. leadership roles, and reiterated full-year guidance) signal meaningful progress on execution and financial leverage. Near-term challenges remain, including an overall revenue decline driven by the China shipment suspension, ongoing quarterly losses and cash burn, typical seasonality (Q3), and the multi-quarter ramp required for new sales hires and clinical enrollment timelines. On balance, the positive operational and balance-sheet developments outweigh the near-term headwinds, but material execution is still required to convert momentum into sustained revenue growth.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(40.00% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
12.32% Insiders
16.67% Mutual Funds
0.29% Other Institutional Investors
66.45% Public Companies and
Individual Investors